Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD)

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Linzess is the first treatment approved for the disease in pediatric patients, the FDA said.

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Ironwood Pharmaceuticals Q2 2025 earnings beat estimates with $85.24M revenue and $0.14 EPS, driven by LINZESS growth and pipeline progress. Shares surged 19.25% pre-market.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong results from prior studies.